Orforglipron vs tirzepatide: compare how the oral GLP-1 pill and the dual GIP/GLP-1 injection differ in weight loss results, dosing, and availability.
Orforglipron is an investigational once-daily oral GLP-1 pill, while tirzepatide (sold as Mounjaro and Zepbound) is an FDA-approved once-weekly injection that activates both GIP and GLP-1 receptors. Across separate clinical trials, tirzepatide has produced greater average weight loss — about 21% of body weight at the 15 mg dose versus roughly 12% with orforglipron 36 mg. No head-to-head trial has ever compared the two drugs, so those numbers come from different studies with different patients.
The short version: tirzepatide is available now and appears more potent; orforglipron is a pill that is not on pharmacy shelves yet.
What Is Orforglipron?
Orforglipron is an oral, non-peptide (small molecule) GLP-1 receptor agonist developed by Eli Lilly. Because it is not a peptide, it survives digestion and can be taken as a tablet — no injection, no refrigeration, and no fasting window.
It is being studied in the ATTAIN program for obesity and the ACHIEVE program for type 2 diabetes. Reported results so far include:
- ACHIEVE-1 (type 2 diabetes): about a 1.6% A1C reduction and roughly 7.9% body weight loss at 40 weeks with the 36 mg dose.
- ATTAIN-1 (obesity without diabetes): up to about 12.4% body weight loss at 72 weeks with 36 mg.
- ATTAIN-2 and ATTAIN-MAINTAIN: studies covering obesity plus type 2 diabetes, and weight maintenance after initial loss.
Orforglipron is not FDA-approved for any use in the United States. Lilly has submitted it for regulatory review, but approval and launch timing are not guaranteed.
What Is Tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist given as a weekly subcutaneous injection. It is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management in adults who meet specific criteria.
Dosing starts at 2.5 mg weekly and steps up roughly every four weeks: 5 mg, 7.5 mg, 10 mg, 12.5 mg, and a maximum of 15 mg. The starting doses are for tolerability, not for treating the condition.
In SURMOUNT-1, adults without diabetes lost an average of about 20.9% of their body weight at 15 mg over 72 weeks. In SURPASS-2, tirzepatide lowered A1C more than semaglutide 1 mg in people with type 2 diabetes.
Orforglipron vs Tirzepatide at a Glance
| Feature | Orforglipron | Tirzepatide |
|---|---|---|
| Route | Oral tablet | Subcutaneous injection |
| Frequency | Once daily | Once weekly |
| Drug type | Small molecule (non-peptide) | Peptide |
| Receptor targets | GLP-1 | GIP and GLP-1 |
| FDA status | Investigational, not approved | Approved (Mounjaro, Zepbound) |
| Top dose studied | 36 mg daily | 15 mg weekly |
| Average weight loss in trials | About 12.4% at 72 weeks | About 20.9% at 72 weeks |
| A1C reduction | About 1.6% at 40 weeks | Up to about 2.4% |
| Food or water restrictions | None reported | None |
| Refrigeration | Not required | Required before first use |
Weight Loss Results: How Big Is the Gap?
Cross-trial comparisons are useful for context but not for predictions. Different enrollment criteria, baseline weights, trial lengths, and discontinuation rules all shift the numbers.
What the data consistently show is that tirzepatide's top dose delivers more average weight loss than any orforglipron dose reported so far. Orforglipron's advantage is not potency — it is convenience and access.
No published trial has directly compared orforglipron and tirzepatide in the same group of patients.
Dosing, Convenience, and Daily Life
- Orforglipron: one tablet daily, taken with or without food and without water restrictions.
- Tirzepatide: one injection weekly using a single-dose pen, kept refrigerated before first use.
For people with needle aversion or heavy travel schedules, an oral option removes real friction. For people who prefer a set-and-forget routine, one weekly injection is simpler than remembering a daily pill.
People looking for a lighter-touch approach sometimes explore lipo-c vs tirzepatide, though injectable lipotropic blends are not FDA-approved for weight loss and have far less evidence behind them.
Side Effects and Safety
Both drugs share the GLP-1 class side effects: nausea, vomiting, diarrhea, constipation, and reduced appetite. These usually ease as the body adjusts, and slower dose increases reduce the risk.
Serious but uncommon risks include pancreatitis, gallbladder disease, and dehydration from persistent vomiting. Tirzepatide carries a boxed warning about thyroid C-cell tumors seen in rodents; the clinical relevance in humans is unknown, and it is not for people with a personal or family history of medullary thyroid cancer or MEN2.
Rapid weight loss also costs lean mass. Discussions about retatrutide muscle loss vs tirzepatide often focus on how much of the total loss is muscle, and the general advice for any GLP-1 — resistance training plus adequate protein — applies here too.
Anyone considering either drug should review their full medication list and health history with a licensed healthcare professional.
Cost, Coverage, and Availability
Tirzepatide is available by prescription, but insurance coverage varies widely and out-of-pocket costs remain high for many people. Compounded tirzepatide became far harder to obtain after the FDA resolved the shortage status, and compounded copies are not FDA-approved.
Orforglipron has no price, no pharmacy availability, and no insurance pathway because it is still under review. Any product sold online as "orforglipron" today should be treated as unverified.
Other Comparisons People Ask About
Orforglipron and tirzepatide are only two entries in a fast-moving field. Questions like retatrutide vs tirzepatide which is better and cagrilintide vs tirzepatide reflect the same underlying question: which mechanism produces the most weight loss with the fewest side effects.
Retatrutide, a triple GIP/GLP-1/glucagon agonist, and cagrilintide, an amylin analog, are both investigational. Neither has been directly compared with orforglipron in a head-to-head trial.
Bottom Line
- Tirzepatide is FDA-approved, injected weekly, and more effective on average in trials.
- Orforglipron is an oral pill that is not yet approved and has shown smaller average weight loss.
- Head-to-head data do not exist, so any ranking rests on indirect comparisons.
If access matters right now, tirzepatide is the only one of the two a clinician can actually prescribe. If swallowing a pill instead of injecting is the deciding factor, orforglipron is worth watching as its regulatory review proceeds.
Frequently Asked Questions
Is orforglipron stronger than tirzepatide?
No. In separate trials, tirzepatide 15 mg produced about 21% average weight loss over 72 weeks, while orforglipron 36 mg produced about 12.4% over the same period. No head-to-head study has directly compared the two drugs, so these figures come from different patient populations.
Is orforglipron a pill or an injection?
Orforglipron is an oral tablet taken once daily, with no food or water restrictions reported in trials. Tirzepatide is a once-weekly subcutaneous injection. That route difference is the main practical distinction between the two.
Is orforglipron FDA-approved?
No. Orforglipron is still investigational in the United States, although its manufacturer has submitted it for regulatory review. Tirzepatide is already approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.